Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

O F Ballester

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
Seminars in Oncology|October 1, 1993
Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicitiesK K Fields, G J Elfenbein, J B Perkins, et al.
Seminars in Oncology|October 1, 1994
High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusionK K Fields, G J Elfenbein, J B Perkins, et al.
Bone Marrow Transplantation|July 1, 1996
Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recoveryO F Ballester, D P Agaliotis, J W Hiemenz, et al.
The American Journal of the Medical Sciences|November 20, 1997
Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantationD P Agaliotis, O F Ballester, T Mattox, et al.
Seminars in Oncology|May 13, 1998
Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancerK K Fields, G J Elfenbein, J B Perkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profileK K Fields, G J Elfenbein, H M Lazarus, et al.
British Journal of Haematology|March 1, 1997
Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myelomaO F Ballester, L C Moscinski, K K Fields, et al.
Bone Marrow Transplantation|January 31, 1998
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiencyO F Ballester, R Tummala, W E Janssen, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
Seminars in Oncology|October 1, 1993
Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicitiesK K Fields, G J Elfenbein, J B Perkins, et al.
Seminars in Oncology|October 1, 1994
High-dose ifosfamide/carboplatin/etoposide: maximum tolerable doses, toxicities, and hematopoietic recovery after autologous stem cell reinfusionK K Fields, G J Elfenbein, J B Perkins, et al.
Bone Marrow Transplantation|July 1, 1996
Phase I-II study of high-dose busulfan and cyclophosphamide followed by autologous peripheral blood stem cell transplantation for hematological malignancies: toxicities and hematopoietic recoveryO F Ballester, D P Agaliotis, J W Hiemenz, et al.
The American Journal of the Medical Sciences|November 20, 1997
Nephrotoxicity of high-dose ifosfamide/carboplatin/etoposide in adults undergoing autologous stem cell transplantationD P Agaliotis, O F Ballester, T Mattox, et al.
Seminars in Oncology|May 13, 1998
Defining the role of novel high-dose chemotherapy regimens for the treatment of high-risk breast cancerK K Fields, G J Elfenbein, J B Perkins, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profileK K Fields, G J Elfenbein, H M Lazarus, et al.
British Journal of Haematology|March 1, 1997
Dexamethasone, cyclophosphamide, idarubicin and etoposide (DC-IE): a novel, intensive induction chemotherapy regimen for patients with high-risk multiple myelomaO F Ballester, L C Moscinski, K K Fields, et al.
Bone Marrow Transplantation|January 31, 1998
High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiencyO F Ballester, R Tummala, W E Janssen, et al.
Pageof 3